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Abstract
The selective delivery of small interfering RNA (siRNA) to metastatic tumors remains a challenging
task. We have developed a nanoparticle (NP) formulation composed of siRNA, a carrier DNA, a
polycationic peptide, and cationic liposomes. The NP was obtained by a self-assembling process,
followed by surface modification with a polyethylene glycol (PEG)-conjugated ligand, anisamide.
The NP was PEGylated and a ligand was presented to target sigma receptor–expressing murine
melanoma cells, B16F10. The lung metastasis model was established by intravenous (IV) injection
of the B16F10 cells into C57BL/6 mice. A mixture of siRNA against MDM2, c-myc, and vascular
endothelial growth factor (VEGF) co-formulated in the targeted NP caused simultaneous silencing
of each of the oncogenes in the metastatic nodules. Two consecutive IV injections of siRNA in the
targeted NP significantly reduced the lung metastasis (~70–80%) at a relatively low dose (0.45 mg/
kg), whereas free siRNA and the nontargeted NP showed little effect. This targeted NP formulation
significantly prolonged the mean survival time of the animals by 30% as compared to the untreated
controls. At the therapeutic dose, the targeted NP showed little local and systemic immunotoxicity
and did not decrease the body weight or damage the major organs.
INTRODUCTION
The lung is a common location of a secondary tumor that has metastasized from the primary
source tumor.1–4 To date, when pulmonary metastases are diagnosed, aggressive surgical
resection is usually performed in order to provide the best chance of a long-term cure.2
Unfortunately, a high relapse rate (~70%) results in a low survival rate (30%) even after
complete resection.2 The relapse of lung metastases usually occurs during chemotherapy,2
thereby indicating that conventional anticancer drugs are no longer effective against the
metastasis. Such a life-threatening condition urgently needs a new systemic treatment.
Among anticancer agents, small interfering RNA (siRNA) has drawn much attention because
of its high specificity, high efficiency, and low toxicity. By targeting the oncogene, siRNA can
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be applied as a therapeutic agent in cancer therapy5; however, the effective delivery of siRNA
remains a challenging task. Despite the development of various delivery carriers for siRNA,
few successful cases have been reported of treating metastatic tumor with systemically
delivered siRNA.6–9
We have earlier shown that our targeted nanoparticle (NP) could deliver significant amounts
of siRNA into the cytoplasm of a xenograft tumor in a nude mouse model, leading to the
silencing of epidermal growth factor receptor, tumor growth inhibition, and
chemosensitization.10 In order to determine whether the targeted NP can also deliver siRNA
to a metastatic tumor, we used an established experimental lung metastasis model by
intravenous (IV) injecting murine melanoma cells (B16F10 cells stably transduced with the
luciferase gene) into C57BL/6 mice. We have performed several feasibility studies which
showed that the targeted NP improved the delivery and efficacy of the siRNA.11 First, the
targeted NP showed an enhanced delivery of cy3-siRNA into the metastatic nodules. The
luciferase gene in the metastatic nodules could be effectively silenced by anti-luciferase siRNA
formulated in the targeted NP; ~70–80% of the luciferase activity was silenced by a single IV
injection (0.15 mg/kg).11 ED50 was only 0.075 mg/kg. The preliminary data showed the
potential of achieving siRNA-based tumor therapy using this targeted NP formulation.
A combination treatment with three different siRNA sequences [MDM2, c-myc, and vascular
endothelial growth factor (VEGF)] has been shown to have a synergistic antiproliferation effect
on the B16 cells.12 We therefore used a combination of these sequences (MDM2/c-myc/VEGF
= 1:1:1, weight ratio) in our therapeutic studies.
RESULTS
In vivo gene silencing study
We encapsulated the combined siRNA sequences into different formulations, treated the lung
metastases-bearing mice on days 10 and 11 with two consecutive IV injections (dose = 0.45
mg/kg), and examined the gene silencing activity using immunohistochemistry (Figure 1) and
western blotting (Figure 2). As shown in Figure 1, only siRNA formulated in the targeted NP
was able to effect simultaneously silencing of MDM2, c-myc, and VEGF in the B16F10 lung
metastases (Figure 1). The data from the western blotting analysis (Figure 2) confirmed the
data obtained from the immunohistochemical analysis.
In vivo antitumor/antimetastasis study
In order to evaluate the therapeutic outcomes, we administered two consecutive injections of
siRNA (0.45 mg/kg, MDM2/c-myc/VEGF = 1:1:1, weight ratio) in different formulations 10
days after IV injection of B16F10 cells, which were stably transduced with a luciferase gene.
As shown in Figure 3a, metastasis nodules were significantly reduced in lungs removed from
the mice treated with siRNA formulated in the targeted NP. Other control treatments, including
free siRNA, siRNA in the nontargeted NP, and control siRNA in the targeted NP, had very
little therapeutic effect (Figure 3a). The hematoxylin and eosin–stained tissue sections also
showed that the lung treated with siRNA in the targeted NP had only a few small nodules, and
most of the lung was free of tumor (Figure 3b). In contrast, metastasis nodules occupied most
of the lung when mice were given other control treatments (Figure 3b). In order to quantify
the B16F10 nodules in the lung, we took one lobe of the excised lung and assayed for the
luciferase activity. As indicated in Figure 3c, siRNA in the targeted NP significantly reduced
the tumor load to 20–30% as compared to the untreated control (P < 0.01), whereas other
control treatments showed no significant effect. The therapeutic outcome was also analyzed
in terms of animal survival (Figure 3d). On day 23, the survival rates for untreated controls,
for mice treated with free siRNA, siRNA in the nontargeted NP, siRNA in the targeted NP,
Li et al. Page 2













and control siRNA in the targeted NP were 0, 0, 50, 90, and 40%, respectively (Figure 3d),
and the mean survival times were 22, 22, 23.5, 28, and 22.5 days, respectively. Only siRNA
in nontargeted or targeted NP significantly improved survival of the animal compared to the
free siRNA formulation (P < 0.05). Control siRNA in the targeted NP did not improve animal
survival compared to the free siRNA (P > 0.05). Although two injections of siRNA in the
nontargeted NP did not reduce the tumor metastasis (Figure 3a–c), the administration of four
such injections resulted in significant improvement in animal survival (Figure 3d).
Toxicity study
At the therapeutic dose (0.45 mg/kg), the targeted NP did not induce significant production of
all analyzed cytokines, including interleukin-6 (IL-6), IL-12, tumor necrosis factor, and
interferon-α (Figure 4). Even after two consecutive injections, the IL-6 and IL-12 levels were
not significantly elevated (data not shown). However, when the dose was increased, the
inflammatory toxicity was significantly enhanced (Figure 4), although still moderate. At the
therapeutic dose, none of the formulations caused elevation in cytokine production in the lung
(Supplementary Figure S1a) (method described in Supplementary Materials and Methods).
Additionally, the body weight did not significantly decrease during treatment at the therapeutic
dose (Supplementary Figure S1b) (method described in Supplementary Materials and
Methods). The targeted NP formulation did not damage the major organs (heart, liver, spleen,
lung, and kidney) that were examined using hematoxylin and eosin staining of the respective
tissue sections (Supplementary Figure S2) (method described in Supplementary Materials and
Methods).
DISCUSSION
siRNA and the carrier DNA (calf thymus DNA) were complexed by protamine into a compact
core, which was further coated with the cationic lipids to form the NP. The surface of the NP
was then modified with a ligand-conjugated polyethylene glycol (PEG)-lipid for targeting the
sigma receptor–expressing B16F10 cells. The preliminary data showed that the siRNA delivery
efficiency into the B16F10 cells was enhanced fourfold by the targeted NP as compared to the
nontargeted NP (NP modified with PEG but without ligand) and could be partially inhibited
by the presence of free ligand.11 In addition, the NP was prepared with a self-assembling
method in a mild condition. Calf thymus DNA was used for improving the particle
complexation, given its high molecular weight. Its limited CpG motif content provides low
immunotoxicity, representing a significant advantage over the plasmid DNA.10,11,13
In order to improve the antitumor/antimetastasis effect, we used combined siRNA sequences
(MDM2/c-myc/VEGF = 1:1:1, weight ratio) so as to attack multiple oncogene pathways.
MDM2 is an inactivator for p53,14 and c-myc serves as an activated transcription factor that
promotes cell proliferation.15 VEGF is a growth factor secreted by the tumor and mediates
angiogenesis and metastasis.16 According to the literature, simultaneous silencing of these
oncogenes by siRNA results in enhanced antiproliferation on the B16 cells.12 Recently, it was
demonstrated that combined delivery of different siRNA sequences resulted in siRNA
competition for incorporation into RNA-induced silencing complex and reduced the efficacy
of RNA interference.17,18 In order to determine whether a combination of the three siRNA
sequences interferes with the gene silencing activity of each sequence, we employed a
quantitative reverse transcription–PCR method to quantify the RNA interference activity of a
single sequence and pooled sequences delivered by the targeted NP (method described in
Supplementary Materials and Methods and Table S1). We did find a sequence competition
effect, with the pooled siRNA formulation showing significantly reduced gene silencing
activity on the c-myc and MDM2 genes but not on the VEGF gene, as compared to the single
siRNA formulations (Supplementary Figure S3) (method described in Supplementary
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Materials and Methods). However, the competition effect was only moderate, and significant
gene knockdown (45–85%) was observed in all the genes when 100 nmol/l pooled siRNA was
used. The data suggest that combined delivery of these three sequences may be acceptable. We
have also checked the RNA interference activity in protein levels by immunocytochemistry.
As shown in Supplementary Figure S4 (method described in Supplementary Materials and
Methods), pooled siRNA in the targeted NP was able to silence MDM2, c-myc, and VEGF in
the B16F10 cells when delivered at a concentration of 100 nmol/l, whereas other control
treatments, including free siRNA, siRNA in nontargeted NP, and control siRNA in targeted
NP showed little effect. There was an enhanced antiproliferation effect on the B16F10 cells
by the targeted NP (data not shown). Both the in vitro and in vivo gene silencing results
(Supplementary Figure S4 and Figures 1 and 2) showed that the gene silencing activity was
highly formulation- and siRNA-sequence-dependent, thereby suggesting that only the delivery
of a sufficient dose of the correct sequences of siRNA results in significant activity. The
antitumor activities of the different formulations were highly correlated to their RNA
interference activities, and only the targeted NP significantly reduced the tumor load (Figure
3a–c).
Although two injections of siRNA in the nontargeted NP did not reduce the tumor load in the
lung (Figure 3a–c), four such injections significantly improved survival of the animal (Figure
3d, P < 0.05). The results suggest that multiple dosing may compensate for the poor delivery
of the nontargeted formulation. However, the prolongation of survival on account of the
nontargeted NP was moderate, although statistically significant. Targeted NP, on the other
hand, with superior delivery efficiency for metastasis,11 not only significantly reduced the
tumor load in the lung (Figure 3a–c), but also prolonged survival by ~30% (Figure 3d). Targeted
NP showed significantly improved therapeutic effects as compared to any of the other siRNA
formulations (Figure 3). Although it is unlikely, it is possible that the off-target effect of the
combined siRNA contributed to the in vivo reduction of tumor load. The off-target effect of
siRNA causing nonspecific gene downregulation was first reported by Scacheri et al.19 It is
speculated that a partial complementary sequence of the siRNA matches with the off-target
genes, and the genes are silenced through the micro-RNA mechanism. This is of particular
concern when multiple siRNA sequences are used. Whether the off-target effect of the siRNA
contributed to the antitumor effect of our formulation is not clear at the present time. However,
the primary goal of this research is to develop a delivery system. The extent to which the off-
target effect contributes to the antitumor activity requires future study. Additionally, the
toxicity study showed that the targeted NP was safe at the therapeutic dose.
In summary, with the improved delivery of siRNA by the targeted NP,11 the corresponding
oncogenes were simultaneously silenced, the mass of lung metastasis was greatly reduced, and
animal survival was significantly prolonged with a relatively low and nontoxic dose (0.45 mg/
kg). We therefore conclude that siRNA formulated in the targeted NP has the potential to
become a useful tool in cancer therapy.
MATERIALS AND METHODS
Materials
DOTAP, cholesterol, and DSPE-PEG2000 were obtained from Avanti Polar Lipids (Alabaster,
AL). Protamine sulfate (fraction X from salmon) and calf thymus DNA (for hybridization,
phenol–chloroform extracted and ethanol precipitated) were purchased from Sigma-Aldrich
(St. Louis, MO). DSPE-PEG2000-anisamide was synthesized in our laboratory using the
methods described earlier.20
B16F10 cells, sigma receptor–positive21 and commonly used for establishing an experimental
lung metastasis model,22 were used in this study. The cells were obtained from American Type
Li et al. Page 4













Culture Collection and stably transduced with GL3 firefly luciferase gene using a retroviral
vector, in Dr. Pilar Blancafort’s laboratory at the University of North Carolina at Chapel Hill.
The cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA).
Primary antibodies (mouse monoclonal antibodies against mouse MDM2, c-myc, luciferase,
β-actin, and rabbit polyclonal antibodies against VEGF) and secondary antibodies conjugated
with horseradish peroxidase (HRP) (goat anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP)
were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA).
siRNA
MDM2 siRNA (target sequence: 5′-GCUUCGGAACAAGAG ACUC-3′), c-myc siRNA
(target sequence: 5′-GAACAUCAUCAUC CAGGAC-3′), VEGF siRNA (target sequence: 5′-
CGAUGAAGCCCUGG AGUGC-3′), and control siRNA (target sequence: 5′-
AATTCTCCGAA CGTGTCACGT-3′) were purchased from Dharmacon (Lafayette, CO) in
deprotected, desalted, and annealed form. The sequences were adopted from the literature.12,
23
Experimental animals
Female C57BL/6 mice of ages 6–7 weeks (weights 16–18 g) were purchased from Charles
River Laboratories (Wilmington, MA). All experiments performed on the animals were in
accordance with and approved by the Institutional Animal Care and Use Committee at
University of North Carolina. Murine model of lung metastasis was established by IV injection
of 2 × 105 B16F10 cells into the C57BL/6 mice.
Preparation of siRNA containing NP
NP were prepared as described earlier.11 Each component (siRNA, calf thymus DNA,
protamine, and cationic liposome) of the formulation was dissolved or prepared in cloning-
grade water with nondetectable endotoxin (Sigma-Aldrich, St. Louis, MO). The solution or
suspension was then sterile filtered (0.22 μm), and the formulations were prepared in a laminar
flow hood using autoclaved tubes and pipette tips. The characteristics of the formulations were
similar to those of formulations reported earlier,11 with a mean diameter of ~110 nm and a zeta
potential of 20–25 mV. The siRNA encapsulation efficiency was >95% as determined using
size exclusion chromatography described earlier.24 The endotoxin level in the formulation was
0.46 endotoxin units (EU)/ml [determined using an endotoxin detection kit (Cambrex Bio
Science, Walkersville, MD)], and ~2.8 EU/kg was injected into each mouse at the dose of 0.45
mg siRNA/kg, which is lower than the upper limit (5 EU/kg) suggested by the US Food and
Drug Administration. The source of the endotoxin was likely from the calf thymus DNA.
In vivo gene silencing study
Tumor-bearing mice were given IV injections of total siRNA (MDM2/c-myc/VEFG = 1:1:1,
weight ratio) at the dose of 0.45 mg/kg formulated in phosphate-buffered saline, the
nontargeted NP, or the targeted NP, on days 10 and 11. One day after the second injection, the
mice were killed and the tumor-loaded lungs were collected for the preparation of paraffin
embedded sections (5-μm thick). Expressions of MDM2, c-myc, and VEGF in the sections
were examined immunohistochemically using the antibodies from a kit [DakoCytomation
Envision + Dual Link System-HRP (DAB+); DakoCytomation, Carpinteria, CA] in accordance
with the product protocol. The nuclei were counterstained with hematoxylin, and the samples
were imaged using a Nikon phase contrast light microscope. Total protein (10 μg) isolated
from the tumor-loaded lung was resolved on a polyacrylamide/sodium dodecyl sulfate gel and
then transferred on to a polyvinylidene difluoride membrane. The membranes were blocked
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with 5% nonfat milk in phosphate-buffered saline for 1 hour and then incubated overnight with
primary antibody at 4 °C. After the membrane had been washed with Tris-buffered saline (1%
Tween 20 in phosphate-buffered saline) five times, it was incubated with the HRP-conjugated
secondary antibody for 1 hour. The peroxidase activity associated with the protein bands was
detected with enhanced chemiluminescence using ECL plus (GE Health Care,
Buckinghamshire, UK) followed by autoradiography.
In vivo metastasis inhibition study and survival analysis
Tumor-bearing mice were given IV injections of total siRNA (MDM2/c-myc/VEFG = 1:1:1,
weight ratio) at the dose of 0.45 mg/kg formulated in phosphate-buffered saline, the
nontargeted NP, or the targeted NP, on days 10 and 11. Control siRNA formulated in the
targeted NP was also prepared as a negative control. On day 17, the mice were killed and the
tumor-loaded lungs were removed. One lobe of each lung was analyzed for luciferase activity
in order to quantify the lung metastasis nodules. The lobe was homogenized in 1 ml of lysis
buffer (0.05% Triton X-100 and 2 mmol/l EDTA in 0.1 mol/l Tris–HCl) followed by
centrifugation at 5,000 rpm for 5 minutes. Ten microliter of the supernatant was mixed with
one hundred microliter of luciferase substrate (Luciferase Assay System; Promega, Madison,
WI), and the luciferase activity was measured using a plate reader (PLATE CHAMELEON
Multilabel Detection Platform; Bioscan, Washington, DC). The rest of the lung was fixed in
3.6% formalin solution overnight and imaged. The fixed lung was processed for paraffin
sections followed by hematoxylin and eosin staining. For the survival analysis study, tumor-
bearing mice were treated on days 10, 11, 17, and 18. The mice were killed if they exhibited
a weight loss >10% or showed ruffled fur.
Cytokine induction assay
The C57BL/6 mice were IV injected with siRNA (MDM2/c-myc/VEGF = 1:1:1) formulated
in the targeted NP at various doses, and the serum cytokine level was determined using the
method described earlier.10,11
Statistical analysis
The data are presented as mean values ± SD. The statistical significance was determined using
one-way analysis of variance. The animal survival data were analyzed using Kaplan–Meier
survival analysis. P values <0.05 were considered significant.
Supplementary Material
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Figure 1. Immunohistochemical analysis of the lung metastasis
Immunohistochemical staining of MDM2, c-myc, and vascular endothelial growth factor
(VEGF) in the B16F10 lung metastatic nodules after treatment with small interfering RNA
(siRNA) in different formulations. Original magnification = ×100. NP, nanoparticle.
Li et al. Page 9













Figure 2. Western blot analysis of the tumor-loaded lung
Western blot analysis of MDM2, c-myc, and vascular endothelial growth factor (VEGF) in the
B16F10 tumor-loaded lung after treatment with small interfering RNA (siRNA) in different
formulations. NP, nanoparticle.
Li et al. Page 10













Figure 3. Antimetastasis efficacy of different small interfering RNA (siRNA) formulations
(a) Images of lungs excised from the tumor-bearing mice on day 17 after two consecutive
treatments. (b) Photographs of the hematoxylin and eosin–stained tissue sections processed
from the excised lungs. Original magnification = ×40. (c) Luciferase activity in the tumor-
loaded lungs on day 17 after two consecutive intravenous (IV) injections of siRNA in different
formulations on days 10 and 11. n = 4–9. ***P < 0.0001 as compared to the siRNA in
phosphate-buffered saline (PBS) formulation. Formulations from left to right: untreated control
(black), siRNA in PBS (red), siRNA in nontargeted nanoparticle (NP) (green), siRNA in
targeted NP (purple), and control siRNA in targeted NP (blue). (d) Survival analysis of B16F10
lung metastases–bearing mice. Tumor-bearing mice were IV injected with different siRNA
formulations on days 10, 11, 17, and 18. n = 10. *P < 0.05, ***P < 0.0001 as compared to the
siRNA in PBS formulation. Formulations: untreated control (black), siRNA in PBS (red),
siRNA in nontargeted NP (green), siRNA in targeted NP (purple), and control siRNA in
targeted NP (blue).
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Figure 4. Serum cytokine analysis
Serum cytokine levels of C57BL/6 mice 2 hours after receiving intravenous injections of small
interfering RNA in targeted nanoparticle at different doses. The data are given as mean values
± SD, n = 4. *P < 0.05; **P < 0.01 as compared to the untreated control. IFN-α, interferon-
α; IL, interleukin; TNF, tumor necrosis factor.
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